“NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research”
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NIH NCI
Contract Value
Not provided
Codes & Classification
Solicitation Number
-
NAICS
-
Classification Code
-
Additional Details
Documents1
The National Cancer Institute (NCI), operating under the Department of Health and Human Services, has issued a Special Notice to publicize a subcontract opportunity at the Frederick National Laboratory for Cancer Research (FNLCR). This notice, posted on SAM.gov, is strictly informational and does not constitute a formal solicitation, invitation for bid, or request for proposal. Interested parties should note that responses to this notice are not considered offers and cannot be accepted to form binding contracts. The government will not reimburse any costs associated with responding to this notice, and any submissions become government property without further discussion or debriefing.
FNLCR is a Government-Owned Contractor-Operated Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The laboratory is managed by Leidos Biomedical Research, Inc. (Leidos Biomed) under prime contract numbers 75N91019D00024 and HHSN261201500003I, providing operations and technical support for NCI. FNLCR collaborates with university, government, and corporate scientists to accelerate the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS.
The scope of this opportunity centers on supporting the NIAID Division of Microbiology and Infectious Diseases (DMID) in the execution of a clinical trial provisionally titled “A Platform Trial to Evaluate Next Generation COVID-19 Vaccines” (NextGen). This initiative involves a series of standardized phase 1 and phase 2 trials designed to generate data that will inform decisions regarding the advancement of next-generation COVID-19 vaccine candidates.
Leidos Biomed is seeking to engage a US-based Contract Development and Manufacturing Organization (CDMO) with the capacity to perform nanofiltration processing, followed by fill and finish operations for a recombinant protein vaccine developed from the 1c-SApNP® platform (CHO Expression System). The deliverables include the filled, finished, and tested drug product, which is intended for use in a US-based Phase 1 clinical trial. The selected CDMO must provide nanofiltration, fill and finish, and release testing services, ensuring all activities are conducted in accordance with current Good Manufacturing Practices (cGMP) and all applicable US Pharmacopeia (USP) standards.
Key requirements for this subcontract opportunity include:
- US-based CDMO status
- Expertise in nanofiltration, fill/finish, and release testing for recombinant protein vaccines
- Compliance with cGMP and USP standards
- Ability to support regulatory documentation and reporting for clinical trial use
The contracting entity for this opportunity is the NIH NCI, a federal office within the National Institutes of Health. The primary point of contact for this notice is Kimberly Iman, who can be reached at [email protected] for further information or to request a copy of Solicitation/RFP No: S26-125. Additional details and future business opportunities with FNLCR can be found at https://frederick.cancer.gov/workwithus/solicitations.
This Special Notice remains active, with a post date of January 6, 2026, and a response date of June 18, 2026. Contractors interested in this opportunity should monitor the referenced sites for updates and ensure their capabilities align with the outlined requirements, particularly in the areas of vaccine manufacturing, quality assurance, and regulatory compliance for clinical trial materials.